ArticleVirchows Archiv : an international journal of pathology2014
Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression.
Article in Virchows Archiv : an international journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Prospective Phase II Trial of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Trial
- Anti-metastatic potential of flavonoids for the treatment of cancers: focus on epithelial-mesenchymal transition (EMT) process.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Natural Killer Cell Mechanosensing in Solid Tumors.Bioengineering (Basel, Switzerland) · 2024Review
- The tumor biological significance of RNF43 and LRP1B in gastric cancer is complex and context-dependent.Scientific reports · 2023Article
- The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.Frontiers in immunology · 2023Review
- Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment.International journal of molecular sciences · 2022Review
- Review
- Article
- EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Review
- Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer.Frontiers in pharmacology · 2021Review
- Review
- Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy.Cancers · 2019Review
- Review
- Inter-heterogeneity and intra-heterogeneity of αEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Article
- Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging.Biophysics reports · 2016Review
- Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.Bioconjugate chemistry · 2015Review
- αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.Clinical & experimental metastasis · 2014Article
- Dual targeting biomimetic liposomes for paclitaxel/DNA combination cancer treatment.International journal of molecular sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the expression of integrins, their ligands, and integrin signaling-related molecules in a cohort of human primary non-small cell lung cancers (NSCLC). Formalin-fixed and paraffin-embedded tissue samples from 215 NSCLC were immunohistochemically stained using antibodies directed against αvβ3, αvβ5, αvβ6, αvβ8, αv, osteopontin, fibronectin, vitronectin, epidermal growth factor (EGFR), vascular endothelial growth factor receptor (VEGFR), and Ki67. Immunostaining of tumor, stroma, and endothelial cells was evaluated separately by quantity and intensity (tumor cells) or intensity (stroma and endothelial cells) expressed in an immunoreactivity score. We studied correlations between the staining patterns of the different markers and of marker expression with clinicopathological data and patient survival. In the majority of NSCLC, each marker was expressed in at least one tumor component. As expected, αv and αv integrin heterodimers were significantly co-expressed, as were integrins and EGFR. Vitronectin was expressed significantly more often in smaller (T-category) and in well-differentiated tumors; Ki67 index was higher in larger (T-category) and in poorly differentiated tumors. No significant correlation was found between any marker expression and gender, venous invasion, lymph vessel invasion, lymph node metastasis, or survival. Although integrin expression does not seem to be associated with indicators of progression of NSCLC, the expression of αvβ3 in 89 % and αvβ5 in 100 % of NSCLC is novel and merits to be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.